FIELD: biotechnology.
SUBSTANCE: obtained modified antisense compounds are able to specifically inhibit the expression of the nucleic acid apo (a). The invention may be used as a medicament for treating, preventing or slowing the progression of disease associated with increased apo (a) or Lp (a), at an individual in need thereof.
EFFECT: reduced expression of apolipoprotein mRNA and protein in an animal, and can be used in medicine.
23 cl, 65 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2013 |
|
RU2748495C2 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| COMPOSITIONS FOR MODULATING EXPRESSION OF SOD-1 | 2015 |
|
RU2704619C2 |
| COMPOSITIONS FOR MODULATION OF ATAXIN 2 EXPRESSION | 2015 |
|
RU2702838C2 |
| COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | 2015 |
|
RU2703411C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2824214C1 |
| ANTISENSE MODULATION OF GCGR EXPRESSION | 2012 |
|
RU2598709C2 |
| MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | 2014 |
|
RU2661781C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2699985C2 |
| MODULATION OF EXPRESSION OF TRANSTHYRETIN | 2011 |
|
RU2592669C2 |
